Ciprofloxacin

Yersinia pestis, Urinary tract infection, acute otitis externa caused by Staphylococcus aureus + 56 more
Treatment
50 FDA approvals
8 Active Studies for Ciprofloxacin

What is Ciprofloxacin

CiprofloxacinThe Generic name of this drug
Treatment SummaryCiprofloxacin is a type of antibiotic used to treat bacterial infections. It is available in oral, intravenous, intratympanic, ophthalmic, and otic forms. The first ciprofloxacin product was approved by the FDA in 1987.
Ciprois the brand name
image of different drug pills on a surface
Ciprofloxacin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cipro
Ciprofloxacin
1987
590

Approved as Treatment by the FDA

Ciprofloxacin, also known as Cipro, is approved by the FDA for 50 uses such as Communicable Diseases and Cystitis .
Communicable Diseases
Cystitis
Urinary Tract Infections
Sinusitis
Urinary tract infection
Osteomyelitis
Urinary Tract Infections
Urinary tract infection
Cystitis
Urinary tract infection
Bone and Joint Infections
Lower respiratory tract infection caused by Escherichia coli
Escherichia urinary tract infection
UTI caused by Citrobacter diversus
UTI caused by Providencia rettgeri
Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae
Febrile Neutropenia
Used to treat Febrile Neutropenia in combination with Piperacillin
prostatitis
UTI caused by Citrobacter frendii
uncomplicated Gonorrhea caused by Neisseria gonorrhoeae
Lower respiratory tract infection caused by Haemophilus parainfluenzae
Acute Sinusitis
UTI caused by methicillin-susceptible Staphylococcus epidermidis
inhaled anthrax caused by Bacillus anthracis
Salmonella typhi
Proteus mirabilis
Proteus mirabilis
Escherichia coli
Infectious diarrhea
Escherichia coli
Klebsiella pneumoniae
Moraxella catarrhalis
Helps manage Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis
UTI caused by Entercococcus faecalis
Serratia marcescens
acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus
Complicated Intra-Abdominal Infections (cIAIs)
Used to treat Complicated Intra-Abdominal Infections (cIAIs) in combination with Metronidazole
Skin Infections
UTI caused by Morganella morganii
acute, uncomplicated Cystitis caused by Escherichia coli
complicated Pyelonephritis caused by Escherichia coli
Febrile Neutropenia
Used to treat Febrile Neutropenia in combination with Piperacillin
Gonorrhea
Escherichia coli
Urinary Tract Infections
Haemophilus influenzae
Pseudomonas aeruginosa
Urinary tract infection
Abdominal Infection
Used to treat Complicated Intra-Abdominal Infections (cIAIs) in combination with Metronidazole
Lower respiratory tract infection caused by Enterobacter cloacae
Klebsiella pneumoniae

Effectiveness

How Ciprofloxacin Affects PatientsCiprofloxacin is an antibiotic that works on both bacteria and viruses. It stops bacteria from growing by binding to their DNA and disrupting the way they reproduce. It is different from other antibiotics because it does not have a resistance to other classes of antibiotics, so it can be useful when other treatments fail. It is also being studied for its possible use in treating malaria, cancer, and AIDS.
How Ciprofloxacin works in the bodyCiprofloxacin stops bacteria from replicating by targeting their DNA gyrase, which helps keep their DNA wound up. By preventing the gyrase from working properly, Ciprofloxacin stops the bacteria's DNA from being able to replicate.

When to interrupt dosage

The recommended portion of Ciprofloxacin is contingent upon the noted condition, including Proteus mirabilis, Conjunctivitis and Cystitis. The dose also deviates in light of the mode of administration (e.g. Kit; Powder, for suspension - Oral or Kit; Suspension) as stated in the table below.
Condition
Dosage
Administration
Yersinia pestis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Urinary tract infection
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
acute otitis externa caused by Staphylococcus aureus
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
inhaled anthrax caused by Bacillus anthracis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Conjunctivitis caused by Haemophilus influenzae
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Serratia marcescens
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Proteus mirabilis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Pseudomonas aeruginosa
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Klebsiella pneumoniae
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Urinary tract infection
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Urinary tract infection
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Urinary Tract Infections
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Proteus mirabilis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
prostatitis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Lower respiratory tract infection caused by Enterobacter cloacae
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Conjunctivitis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Cystitis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Gonorrhea
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
UTI caused by methicillin-susceptible Staphylococcus epidermidis
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic
Urinary Tract Infections
, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL
Auricular (otic), , Suspension, Suspension - Auricular (otic), Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate, Solution, concentrate - Intravenous, Kit, Ointment, Ointment - Ophthalmic, Suspension - Oral, Solution - Auricular (otic), Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Auricular (otic); Intratympanic, Suspension - Auricular (otic); Intratympanic

Warnings

Ciprofloxacin Contraindications
Condition
Risk Level
Notes
External auditory canal structure
Do Not Combine
Fungal ear infection
Do Not Combine
Pulse Frequency
Do Not Combine
Tympanic Membrane Perforation
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ciprofloxacin may interact with Pulse Frequency
There are 20 known major drug interactions with Ciprofloxacin.
Common Ciprofloxacin Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Ciprofloxacin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Ciprofloxacin.
Acetaminophen
Major
The metabolism of Acetaminophen can be decreased when combined with Ciprofloxacin.
Acyclovir
Major
The metabolism of Acyclovir can be decreased when combined with Ciprofloxacin.
Agomelatine
Major
The serum concentration of Agomelatine can be increased when it is combined with Ciprofloxacin.
Ciprofloxacin Toxicity & Overdose RiskAn overdose of ciprofloxacin may lead to nausea, vomiting, abdominal pain, urinary crystals, reduced kidney function, and decreased urine production. Depending on the severity of the overdose, patients may need prednisone, dialysis, or supportive care. Animal studies have shown that doses higher than the recommended dose may cause gastrointestinal issues in the mother and potentially lead to miscarriage. Mutagenicity tests have yielded positive results in some cases, but no carcinogenicity or tumorigenicity has been shown in rats and mice at doses of up to 300 times the maximum recommended clinical dose. Fertility of rats has not been affected by
image of a doctor in a lab doing drug, clinical research

Ciprofloxacin Novel Uses: Which Conditions Have a Clinical Trial Featuring Ciprofloxacin?

Currently, there are no active trials assessing the potential of Ciprofloxacin to treat Pseudomonas aeruginosa, Escherichia coli and Cystitis.
Condition
Clinical Trials
Trial Phases
Febrile Neutropenia
3 Actively Recruiting
Phase 2, Not Applicable
Otitis
3 Actively Recruiting
Not Applicable
Tympanostomy tube insertion
0 Actively Recruiting
Escherichia coli
0 Actively Recruiting
Urinary tract infection
0 Actively Recruiting
Yersinia pestis
0 Actively Recruiting
Cystitis
0 Actively Recruiting
Otitis
0 Actively Recruiting
Pseudomonas aeruginosa
0 Actively Recruiting
Gonorrhea
0 Actively Recruiting
inhaled anthrax caused by Bacillus anthracis
0 Actively Recruiting
Urinary Tract Infections
0 Actively Recruiting
Plague
0 Actively Recruiting
Corneal Ulcer
0 Actively Recruiting
acute otitis externa caused by Staphylococcus aureus
0 Actively Recruiting
UTI caused by methicillin-susceptible Staphylococcus epidermidis
0 Actively Recruiting
Lower respiratory tract infection caused by Enterobacter cloacae
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Urinary tract infection
0 Actively Recruiting

Ciprofloxacin Reviews: What are patients saying about Ciprofloxacin?

5Patient Review
12/28/2021
Ciprofloxacin for Bacterial Urinary Tract Infection
Not only did this effectively treat my UTI, but it also cleared up my SIBO symptoms. Much more expensive antibiotics haven't been able to do that, so I'm really happy with this treatment.
4.7Patient Review
2/25/2022
Ciprofloxacin for Acute Maxillary Sinus M. Catarrhalis Bacteria Infection
I had been struggling with chronic sinusitis for years and even had two surgeries. When things got really bad, my doctor prescribed me amoxicillin; while it did help somewhat, I decided to do my own research and purchased Cipro in Europe without a prescription. Immediately after taking the recommended dosage (250mg 2x day), I felt incredible-- better than I ever thought possible.
4.3Patient Review
9/22/2020
Ciprofloxacin for Infection Within the Abdomen
Worked well for the infection but had a terrible side effect.I had pain and swelling on my wrist which I was told was due to tendon rupture-an adverse effect of ciprofloxacin i was not warned of.
4.3Patient Review
5/1/2021
Ciprofloxacin for Bacterial Urinary Tract Infection
I am a female age 68 and by 3rd day I had relief. I drank 3 quarts of water daily and had no problems. I read everything provided. No sugar and no alcohol. Worked fine for me!
3Patient Review
12/22/2020
Ciprofloxacin for Bacterial Urinary Tract Infection
The side effects were really tough to get through, but the medication started working after a few days. I had chills and shakes, pain in my limbs and back, and my urine smelled incredibly strong (which I wasn't expecting). If you can make it past the initial hurdle, this treatment is worth it.
2.7Patient Review
3/17/2021
Ciprofloxacin for Diverticulitis
I got sick almost immediately after taking this medication, with symptoms including dizziness, nausea, and muscle aches. I had to take a lower dosage of the drug and split it up with Flagyl to make sure that it wasn't the Cipro itself that was making me ill. After reading the Black Label warning, my PCP switched me to Bactrim. I'll review it once I've taken it.
2Patient Review
5/25/2022
Ciprofloxacin for Bacterial Urinary Tract Infection
While this medication did cure my UTI, the side effects were really unpleasant. I experienced burning pain in my legs, nausea, and lightheadedness. Thankfully, these symptoms have mostly subsided now.
1.7Patient Review
6/2/2022
Ciprofloxacin for Bacterial Urinary Tract Infection
I was given this medication for prostatis, but after using it for a month I started to experience burning sensations in my legs and palms. I'm stopping the medication now, and hopefully the side effects will go away. If you've used this drug before, please share your experiences with side effects.
1.7Patient Review
9/14/2022
Ciprofloxacin for Inflammation of the Bladder
PLEASE use extreme caution when taking this medication. My otherwise mentally healthy relative committed suicide after taking it for less than two months.
1Patient Review
12/7/2020
Ciprofloxacin for Abscess Within the Abdomen
I.V. Ciprofloxacin was totally ineffective at treating an infection of Morganella Morganii. All i got from it was swollen spine joints making it impossible to stand up straight.
1Patient Review
2/19/2022
Ciprofloxacin for Intestine Infection due to the Shigella Bacteria
My colleague lost her ability to walk normally, had involuntary muscle spasms, and a debilitating headache after taking this drug. She also had fevers and chills. Do not recommend.
1Patient Review
6/6/2022
Ciprofloxacin for Heart Valve Infection caused by Haemophilus
Avoid this pill at all cost! I had terrible side effects, and it turns out that many people do. Not only does it damage DNA, but it also makes things much worse. If you're reading this and have been affected by this drug, load up on magnesium. It'll help repair the damage and calm your nervous system.
1Patient Review
7/25/2022
Ciprofloxacin for infection caused by bacteria
I was given this medication for stomach bacteria, but after taking just two pills I felt terrible. My skin felt like it was going to break out in hives and I was so lethargic. I got up overnight to use the restroom and I couldn't move my left hip. It was terrifying. I have no idea why doctors would prescribe this poison to anyone!
1Patient Review
4/7/2022
Ciprofloxacin for Bacterial Urinary Tract Infection
If you have EDS, avoid this drug as it has been known to cause ligament problems. Those with EDS already have loose ligaments and need to be careful about what medications they take.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ciprofloxacin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Cipro a strong antibiotic?

"The best antibiotic is the one that will kill the specific type of bacteria causing the infection and that is not too toxic for the person who is taking it.

Ciprofloxacin is quite a strong antibiotic, however, there are other stronger antibiotics that can treat more types of infections. The best antibiotic is the one that will kill the specific type of bacteria causing the infection."

Answered by AI

What are the side effect of ciprofloxacin?

"[The text lists various symptoms which may include] nausea, vomiting, stomach pain, heartburn, diarrhea, vaginal itching and/or discharge, pale skin, and unusual tiredness."

Answered by AI

What is ciprofloxacin used for?

"urinary tract infections (UTIs), such as cystitis and kidney infections skin infections, such as cellulitis and body (systemic) MRSA ear infections sinus infections eye infections

Ciprofloxacin is an antibiotic belonging to the fluoroquinolone group. It is used to treat serious infections, as well as infections where other antibiotics have failed. It can be used to treat infections such as pneumonia, UTIs, cellulitis, MRSA, ear infections, sinus infections, and eye infections."

Answered by AI

What type of infections does ciprofloxacin treat?

"Pneumonia and some lower respiratory infections, urinary tract infections, gonorrhea, and some infections of the digestive tract can be treated with amoxicillin. It is also effective against some serious skin, bone, and joint infections, prostate gland infections, and infectious diarrhea."

Answered by AI

Clinical Trials for Ciprofloxacin

Image of Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center in Cleveland, United States.

Alio Smart Patch Monitoring for Cancer Patients

18 - 65
All Sexes
Cleveland, OH
Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monitoring of vital signs and blood levels. The goal is to see if potential side effects can be identified and treated sooner. During this study, participants will wear an Alio Smartpatch™. The Alio Smartpatch™ is a wireless remote monitoring system. This device will measure participants' vital signs and blood levels. Participants will also be asked to use continuous glucose monitors to measure their glucose levels. The data collected on each participant from these devices will be remotely monitored at all times by clinical staff at a company known as Quantify Remote Care. If a participant's results look like they are experiencing a side effect, the participant will be contacted immediately by Quantify Remote Care team. The Quantify Remote Care team will function as an extension of the participant's cancer clinical team and will relay any significant issues back to them. Quantify Health also provides dietary and mental health support as needed for all participants.
Recruiting
Has No Placebo
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer CenterAlberto Montero, MD, MBA
Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center
Image of Denver Health and Hospital Authority in Denver, United States.

Interventions for Ear Infections

6 - 17
All Sexes
Denver, CO
This study aims to improve care and reduce unnecessary antibiotic prescribing for children with ear infections. The study will compare the effectiveness of a "gold standard" to a hybrid intervention combined with this gold standard, in order to identify steps to increase parent satisfaction for child ear infection care. The "gold standard" approach is a Health System Level Intervention. On its own, it involves clinician education, tools in electronic medical records, and audit and feedback reports for clinician prescribing habits. The hybrid intervention includes the elements of the health systems level intervention in addition to a Shared Decision-Making component, which allows for both an increase in the role parents play in their child's care, as well as clinician education for how to use this method. The goals of this work are to increase parent satisfaction, reduce antibiotics taken for childhood ear infections, align medical care with the current national guidelines, and evaluate differences in the two intervention groups. Both groups will be evaluated for implementation outcomes to improve dissemination and scalability for future use of these models in antibiotic prescribing for children with ear infections. This study will recruit a diverse group of patients and clinicians to complete surveys, parents to participate in focus groups, and clinicians and administrators to be interviewed in order to meet study aims and receive sufficient feedback on the interventions performed. There are two hypotheses for this research: 1. The Hybrid Intervention will have higher parent satisfaction and reduced antibiotic use compared to the Health-System Level Intervention and 2. The Hybrid Intervention will be more challenging to implement than the Health-System Level Intervention, but will be preferred by parents, clinicians, and administrators.
Recruiting
Has No Placebo
Denver Health and Hospital Authority (+2 Sites)Holly Frost, MD
Have you considered Ciprofloxacin clinical trials? We made a collection of clinical trials featuring Ciprofloxacin, we think they might fit your search criteria.Go to Trials
Image of Denver Health and Hospital Authority in Denver, United States.

Shorter Antibiotic Courses for Ear Infections

2 - 17
All Sexes
Denver, CO
The overarching goal of this study is to evaluate the effectiveness and implementation outcomes of two low-cost interventions of different intensities to increase prescribing of recommended short antibiotic durations for acute otitis media (AOM) for children 2 years of age and older. A multi-center cluster randomized controlled trial using a hybrid type 2 implementation effectiveness design will be used to evaluate interventions. The High-Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields, whereas the Low-Intensity intervention will include clinician education and EHR changes. In total, 46 community-based clinics and/or urgent care centers across two distinct geographic regions in the United States will be randomized to one of the two interventions. The Practical Robust Implementation and Sustainability Model (PRISM) will be used to guide implementation and the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework will be used to evaluate outcomes. A mixed-methods approach will be used in the pre-implementation and evaluation phases and will utilize quantitative analyses, semi-structured interviews, focus groups, surveys, and cost analyses. National stakeholders at the American Academy of Pediatrics and the Centers for Disease Control and Prevention will assist with dissemination of findings and scaling of interventions.
Waitlist Available
Has No Placebo
Denver Health and Hospital AuthorityTimothy C Jenkins, MD
Image of Hackensack Meridian Health in Hackensack, United States.

Antibiotics for Protecting Gut Bacteria During Stem Cell Transplant

18+
All Sexes
Hackensack, NJ
The purpose of this study is to see how different antibiotics affect the community of friendly bacteria existing in the intestinal tract (gut). Under normal circumstances, these friendly bacteria are not harmful and they help with normal bodily functions such as digestion. When these bacteria are absent, several complications may occur, such as infections with harmful bacteria or other inflammatory reactions, that can complicate the stem cell transplant course. Treatment with antibiotics or chemotherapy is known to kill off these friendly bacteria. In this study we compare the effects of different antibiotics on the community of friendly bacteria in the gut. For microbiota-related biomarker analysis, optional urine samples (MSKCC patients only) will be collected at baseline, 7 +/-2 days after initiation of antibiotic therapy, and on post-transplant days +28, +56 and +100 (+/- 7days).
Phase 2
Waitlist Available
Hackensack Meridian Health (+1 Sites)Susan Seo, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security